Status:

COMPLETED

A First in Human Study to Evaluate Safety, Tolerability, Pharmacology of HS-10374 in Healthy Subjects

Lead Sponsor:

Jiangsu Hansoh Pharmaceutical Co., Ltd.

Conditions:

Psoriasis

Eligibility:

All Genders

18-45 years

Phase:

PHASE1

Brief Summary

The purpose of this first-in-human study is to evaluate the safety, tolerability, and pharmacokinetics (PK) of HS-10374 in healthy subjects.

Eligibility Criteria

Inclusion

  • Healthy male or female subjects between the ages of 18-45 years
  • Have no reproductive potential; or agree to use a highly effective method of contraception, and refrain from donating sperm or eggs during the study period and for at least 6 months after last dosing
  • Have signed the informed consent form approved by the IRB

Exclusion

  • Have a clinically significant infection currently or within past 30 days, or have a history of active tuberculosis; or have positive screening test for infectious disease, including tuberculosis, viral hepatitis, AIDS and syphilis
  • Have a history of or current allergic disease
  • Have a history of drug or alcohol abuse or currently positive test result(s) for alcohol or drugs of abuse
  • Smokers smoked ≥5 cigarettes per day within past 3 months or have a positive test result for nicotine
  • Clinically significant abnormal physical examination, vital signs, clinical laboratory values, ECGs or imaging tests
  • Pregnant or breastfeeding female subjects
  • Have received hormone-based contraceptives, drugs that prolong the QT interval, drugs that may cause drug interactions with investigational product, immunosuppressants, vaccines or other drugs within a specific period

Key Trial Info

Start Date :

November 13 2021

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

March 24 2023

Estimated Enrollment :

84 Patients enrolled

Trial Details

Trial ID

NCT06033742

Start Date

November 13 2021

End Date

March 24 2023

Last Update

September 13 2023

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Huashan Hospital Affiliated to Fudan University

Shanghai, Shanghai Municipality, China, 200040

A First in Human Study to Evaluate Safety, Tolerability, Pharmacology of HS-10374 in Healthy Subjects | DecenTrialz